Endocrine approaches for the treatment of early and advanced breast cancer in postmenopausal women

被引:8
作者
Tobias, JS [1 ]
机构
[1] Middlesex Hosp, Meyerstein Inst Clin Oncol, London WIT 3AA, England
关键词
endocrine approaches; postmenopausal women; breast cancer;
D O I
10.1016/j.biocel.2004.03.015
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Preventing clinical progression is the major treatment goal for both early and advanced breast cancer. For hormone-responsive cases (about 70% of the total), this can necessitate the use of sequential hormone therapies at various points during the patient's life. Newer hormonal therapies, such as the third-generation aromatase inhibitor anastrozole, are now competing with tamoxifen as first choice endocrine therapy in breast cancer. In addition, a further non-steroidal aromatase inhibitor letrozole has been shown to be beneficial when given at completion of 5 years adjuvant tamoxifen. In light of these new data, current treatment paradigms need to be reviewed. Already well established as second-line treatments for advanced breast cancer, the improved risk:benefit profiles of anastrozole and letrozole compared with tamoxifen mean that these agents are now also recognised alternative treatments in the first-line relapse setting. More recent studies demonstrate that anastrozole may also have an improved risk:benefit profile compared with tamoxifen when used as initial adjuvant therapy in early breast cancer. Anastrozole is also being evaluated as a preventative treatment in women at high risk of developing breast cancer. A new addition to the endocrine treatment armamentarium is the oestrogen receptor antagonist fulvestrant, which, unlike tamoxifen, has no agonist effects. Fulvestrant is at least as effective as anastrozole in the second-line treatment of advanced breast cancer, and provides similar benefits to tamoxifen when used as first-line therapy in patients with advanced, hormone receptor-positive tumours. (C) 2004 Elsevier Ltd. All rights reserved.
引用
收藏
页码:2112 / 2119
页数:8
相关论文
共 47 条
  • [1] *AM CANC SOC, 1998, BREAST CANC FACTS FI
  • [2] Aromatase inhibitors in the treatment of postmenopausal breast cancer
    Bajetta, E
    Zilembo, N
    Bichisao, E
    [J]. DRUGS & AGING, 1999, 15 (04) : 271 - 283
  • [3] Baum M, 2002, LANCET, V359, P2131
  • [4] Baum M., 2003, CANCER, V98, P1802, DOI DOI 10.1002/CNCR.11745
  • [5] Bisagni G, 1996, ANN ONCOL, V7, P99
  • [6] BOCCARDO F, 2003, BREAST CANC RES T S1, V82, P56
  • [7] Anastrozole versus tamoxifen as first-line therapy for advanced breast cancer in 668 postmenopausal women:: Results of the tamoxifen or arimidex randomized group efficacy and tolerability study
    Bonneterre, J
    Thürlimann, B
    Robertson, JFR
    Krzakowski, M
    Mauriac, L
    Koralewski, P
    Vergote, I
    Webster, A
    Steinberg, M
    von Euler, M
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2000, 18 (22) : 3748 - 3757
  • [8] Phase III, multicenter, double-blind, randomized study of letrozole, an aromatase inhibitor, for advanced breast cancer versus megestrol acetate
    Buzdar, A
    Douma, J
    Davidson, N
    Elledge, R
    Morgan, M
    Smith, R
    Porter, L
    Nabholtz, J
    Xiang, X
    Brady, C
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2001, 19 (14) : 3357 - 3366
  • [9] Buzdar A, 2001, CLIN CANCER RES, V7, P2620
  • [10] Anastrozole, a potent and selective aromatase inhibitor, versus megestrol acetate in postmenopausal women with advanced breast cancer: Results of overview analysis of two phase III trials
    Buzdar, A
    Jonat, W
    Howell, A
    Jones, SE
    Blomqvist, C
    Vogel, CL
    Eiermann, W
    Wolter, JM
    Azab, M
    Webster, A
    Plourde, PV
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 1996, 14 (07) : 2000 - 2011